Related Experiment Video
Updated: Jul 7, 2026
07:38
Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Pharmacogenomics of acute leukemia
1Research Center Charles Bruneau, CHU Sainte-Justine, Montréal, Quebec, H3T 1C5, Canada.
Pharmacogenomics
|February 5, 2008
Summary
Pharmacogenomics can improve leukemia treatment by linking genetic variations to drug responses. Understanding these genetic factors is crucial for better outcomes in acute lymphoblastic leukemia and acute myeloid leukemia.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Cancer chemotherapy often causes severe side effects and treatment failure due to individual variability.
- Leukemia, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), presents challenges in treatment efficacy and prognosis, especially in adults with AML and children with ALL.
- Pharmacogenomics offers a promising approach to personalize cancer therapy by examining genetic influences on drug response.
Purpose of the Study:
- To review pharmacogenetics studies in pediatric and adult leukemia patients.
- To identify associations between genetic polymorphisms and treatment responses in acute lymphoblastic leukemia and acute myeloid leukemia.
- To explore the role of gene polymorphisms in drug metabolism and efficacy for leukemia treatment.
Main Methods:
- Systematic review of existing pharmacogenetics literature.
- Analysis of studies focusing on genetic polymorphisms in leukemia patients.
- Correlation of genetic variations with clinical outcomes and drug responses.
Main Results:
- Genetic polymorphisms significantly influence the efficacy and toxicity of leukemia chemotherapeutics.
- Specific gene variants are associated with varied treatment responses in both acute lymphoblastic leukemia and acute myeloid leukemia.
- Understanding these genetic associations can help predict treatment success and minimize adverse drug reactions.
Conclusions:
- Pharmacogenomics is essential for optimizing leukemia treatment strategies.
- Personalized medicine approaches based on genetic profiles can improve patient outcomes in acute lymphoblastic leukemia and acute myeloid leukemia.
- Further research into pharmacogenetics will enhance the effectiveness and safety of leukemia therapies.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:29Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...